JP Morgan Maintains Overweight on Jazz Pharmaceuticals, Raises Price Target to $276

Benzinga · 08/04 18:52
JP Morgan analyst Jessica Fye maintains Jazz Pharmaceuticals (NASDAQ:JAZZ) with a Overweight and raises the price target from $265 to $276.